SOLE MATES: Joburg’s running clubs — building community one kilometre at a time

The sharp decline in childhood vaccination rates across Michigan during the initial months of the Trump administration represents a significant inflection point in American public health policy—and a potential paradigm shift with considerable implications for European investors eyeing the North American healthcare market. According to Reuters analysis of state epidemiological data, Michigan experienced a measurable drop in immunization coverage among children under five during this period, attributed largely to the influence of vaccine-skeptic Health Secretary Robert F. Kennedy Jr. on federal immunization guidance and policy implementation. This represents not merely a localized phenomenon but rather an early indicator of systematic policy reorientation that could reshape the American healthcare landscape across multiple states. For European pharmaceutical and health-technology companies, this development creates a complex investment landscape characterized by both opportunity and risk. The traditional assumption—that American healthcare markets operate within relatively stable regulatory and consumer-preference frameworks—no longer holds unambiguous validity. **Market Implications for European Investors** The vaccination rate decline signals several concurrent market dynamics. First, it indicates growing consumer skepticism toward conventional public health recommendations, creating space for alternative health solutions and supplementary wellness products. European companies specializing in immune-support supplements, naturopathic alternatives, and personalized health monitoring technologies may find receptive